GLP-1 and Gallbladder Disease: What the Meta-Analysis of 76 Trials Shows

Every GLP-1 label carries a line about gallbladder disease, usually read quickly and filed under "rare side effects." The largest pooled analysis of the trial data says it deserves more attention than that one line implies — and, notably, the risk isn't uniform across everyone taking these drugs.

The meta-analysis

Researchers pooled data from 76 randomized clinical trials covering 103,371 patients to specifically quantify GLP-1 receptor agonists' effect on gallbladder and biliary disease risk¹. This is a meta-analysis of randomized, placebo-controlled data — not an observational database study vulnerable to confounding by who happens to get prescribed a GLP-1 — which makes its findings unusually solid for this kind of side-effect signal.

The topline number, and why the subgroup breakdown matters more

Across all 76 trials, GLP-1 receptor agonist use was associated with a relative risk of 1.37 (95% CI, 1.23-1.52) for gallbladder or biliary disease overall, with cholelithiasis (gallstones) specifically at a relative risk of 1.27 (95% CI, 1.10-1.47), cholecystitis (gallbladder inflammation) at 1.36 (95% CI, 1.14-1.62), and broader biliary disease at 1.55 (95% CI, 1.08-2.22)¹. But the headline 1.37 figure blends two very different populations. When the analysis split trials by indication, weight-loss trials specifically showed a relative risk of 2.29 (95% CI, 1.64-3.18), versus 1.27 (95% CI, 1.14-1.43) in trials for type 2 diabetes or other indications — a statistically significant interaction (P<0.001)¹. In plain terms: if you're taking a GLP-1 specifically for weight loss, the trial-level gallbladder risk in this dataset ran meaningfully higher than for people taking the same drug class for diabetes.

Why weight loss itself is the likely driver, not the drug alone

The analysis also found the risk tracked dose and duration: higher-dose trials showed a relative risk of 1.56 (95% CI, 1.36-1.78) versus 0.99 (95% CI, 0.73-1.33) for lower doses, and longer-duration use showed 1.40 (95% CI, 1.26-1.56) versus 0.79 (95% CI, 0.48-1.31) for shorter duration — both statistically significant interactions¹. That pattern — more risk with higher doses, longer use, and specifically in weight-loss trials — points toward the well-established mechanism behind rapid-weight-loss gallstones generally: fast fat loss increases cholesterol saturation in bile and reduces gallbladder motility, the same physiological chain that makes gallstones a known risk after bariatric surgery or aggressive dieting, not just GLP-1 use specifically. It's consistent with what the trial data itself shows: Wegovy's FDA label reports cholelithiasis in 1.6% of injection-treated adults versus 0.7% on placebo, and 2.5% of tablet-treated patients versus 1% on placebo, with cholecystitis at 0.6% versus 0.2%² — real but modest absolute numbers, consistent with an elevated relative risk on a fairly low baseline rate. We cover the exact label language for this and the class's other warnings in GLP-1 boxed warnings: what the label actually says.

What this means in practice

A roughly doubled relative risk sounds alarming in isolation, but gallbladder disease remains uncommon overall, and the absolute numbers in the label data — low single digits — reflect that. What the data does support is being alert to the symptoms: sudden, severe upper-right abdominal pain, pain after eating fatty food, nausea, or fever warrant a call to your prescriber rather than being written off as routine GI side effects, which are covered separately in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported. The dose-and-duration relationship is also a reasonable argument for not rushing titration faster than your prescriber recommends purely to reach a higher dose sooner — a slower, medically-guided pace doesn't eliminate the risk, but the data doesn't support that faster is safer here either.

Where this fits your provider decision

A program that's never mentioned gallbladder disease as part of its intake or side-effect counseling is skipping a real, quantifiable risk that the trial data actually supports discussing — not a fringe internet claim. Ask directly whether your prescriber's practice reviews gallbladder symptoms as part of ongoing check-ins, particularly if you're losing weight quickly. See how we weigh real medical oversight in our Value Score methodology, and compare pricing across verified programs on our semaglutide and tirzepatide price boards.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.